Season's Savings | ₹5/mo for 3 months
₹199/month after first 3 months. Renews automatically. Terms apply.
AMGN Today - Aug 11: Mixed Signals in the Market
Failed to add items
Sorry, we are unable to add the item because your shopping basket is already at capacity.
Add to cart failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
Written by:
About this listen
So, what happened? Amgen slid down by 0.75%. It didn’t really catch a break today, even though it wasn’t a crazy drop. The trading volume was right on average, so it wasn’t like everyone was panicking or anything. Just a slow bleed, you know?
Now, why did it happen? Well, there were a few things buzzing around. First off, there's chatter about Charles Schwab Trust upping their stake in Amgen. That usually sounds like good news, but it didn’t really light a fire under the stock. Then, there’s the news about Amgen’s director, Charles Holley, getting a stock award and reporting his holdings. Again, cool stuff for insiders, but it didn’t seem to move the needle for everyone else.
On the flip side, Guggenheim raised Amgen’s price target to $388, which is a positive sign. But honestly, it feels like the market is just digesting all this info without any big reactions. So, nobody really knows why it got smoked today. Just one of those days, I guess.
Looking ahead, Amgen’s Q2 earnings call had some solid analyst questions, so there’s definitely some interest in what they’re doing. That could be something to keep an eye on, especially if they drop any juicy details.
Alright, that’s a wrap for today! Just remember, this is all for fun and info – not financial advice. Stay chill and invest smart! Catch you later!
adbl_web_anon_alc_button_suppression_t1
No reviews yet